Technology ID
E-263-2013-0

Antibodies for Rabies Post-exposure Prophylaxis or Antiviral Therapy of Clinical Rabies

Linked ID
TAB-3307
Inventors
Todd Smith (CDC)
Xianfu Wu (CDC)
Lead Inventors
Todd Smith (CDC)
Co-Inventors
Xianfu Wu (CDC)
Applications
Research Materials
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Antibodies can be used directly in rabies post-exposure prophylaxis or antiviral therapy of clinical rabies
  • Method offers support to improve the spectrum of biological activity against non-rabies lyssaviruses
  • Antibody phage library can be used for additional research
Competitive Advantages
  • Currently, there are no specific treatments available to treat and cure clinical rabies after the onset of symptoms
  • Commercial anti-rabies immune globulins (Ig) do not neutralize other lyssaviruses, such as Lagos Bat, Mokola (MOK) and West Caucasian Bat viruses (WCBV)

Request More Info

Licensing Contact